Evidence map›Paper›PMID 42334062›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Nick Corriveau-Lecavalier, Neus Falgàs, Deepti Putcha, Jonathan Graff-Radford, Keir X X Yong, Baayla D C Boon, Rosaleena Mohanty, Eric Westman, Colin Groot, David T Jones and 27 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Nick Corriveau-LecavalierDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Neus FalgàsAlzheimer's Unit and Other Cognitive Disorders, Neurology Service, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona -IDIBAPS, Barcelona, Spain.
Deepti PutchaDepartment of Psychiatry, Frontotemporal Disorders Unit, Massachusetts General Hospital & Department of Neurology, Boston, Massachusetts, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Keir X X YongQueen Square Institute of Neurology, University College London, London, UK.
Baayla D C BoonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Rosaleena MohantyDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.
Eric WestmanDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.
Colin GrootAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Lea T GrinbergDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Gil D RabinoviciEdward and Pearl Fein Memory and Aging Center, Weill Institute of Neuroscience, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, California, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Dustin B HammersDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Suzanne E SchindlerKnight Alzheimer Disease Research Center, St. Louis, Missouri, USA.
Inga AtonsdottirRichman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Department of Psychiatry & Behavioral Sciences, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA.
Elizabeth K RhodusSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Jonathan M SchottDementia Research Centre, University College London, Institute of Neurology, London, UK.
Ignacio Illán-GalaCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Chukwuanugo OgbuaguDepartment of Community Medicine, Centre for Primary Health Care, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.
Jorge J Llibre GuerraDepartment of Neurology, Washington University School of Medicine in, St. Louis, Missouri, USA.
Ruth PetersDepartment of Psychology University of New South Wales, Sydney, New South Wales, Australia.
Erin L AbnerSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Carla AbdelnourDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Albert LladóAlzheimer's Unit and Other Cognitive Disorders, Neurology Service, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona -IDIBAPS, Barcelona, Spain.
Renaud La JoieEdward and Pearl Fein Memory and Aging Center, Weill Institute of Neuroscience, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, California, USA.
Leonardo Cruz de SouzaInstituto de Ciências Biológicas, Programa de Pós-Graduação em Neurociências, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Neguine RezaiiDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital & Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
Dror ShirDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Yolande A L PijenburgAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois, USA.
Bradford C DickersonDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital & Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
Paul AisenUniversity of California San Diego, San Diego, California, USA.
Rik OssenkoppeleDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Rema RamanAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.

Funding

Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Instituto de Salud Carlos III JR22/00014NIA NIH HHS P30 AG072946NIH HHS P30 AG 062677NIH HHS R01-AG075802NIH HHS R01-AG50603
6 · The paper itself

Abstract

Patients with atypical variants of Alzheimer's disease (AD) often present at a younger age with predominantly non-amnestic impairments and a more aggressive disease course. Historically, individuals with atypical presentations have not been included in large-scale clinical trials, which typically focus on late-onset, sporadic amnestic-predominant AD. Consequently, treatment options and research efforts specific to atypical AD remain limited. The emergence of amyloid-targeting therapies that slow disease progression underscores these challenges, as evidence supporting their efficacy in early-onset amnestic and non-amnestic AD variants is scarce. This perspective article argues that atypical AD represents an excellent disease model for clinical trials and proposes strategies to address critical gaps in clinical trial design for this population. Key considerations include optimizing participant selection approaches, establishing syndrome-specific or surrogate biological and clinical endpoints, and fostering advocacy to enhance early and accurate diagnosis, equitable representation, and outcomes for these populations.

Indexed as

Alzheimer DiseaseClinical Trials as TopicDisease ProgressionHumansatypical Alzheimer's diseaseclinical trialsdementiaheterogeneity

Identifiers

PMID42334062
PMCPMC13288256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.